May 10, 2020
Hospitals may realize important savings by helping recently discharged patients control their diabetes with DarioHealth®
Reducing readmission rates can lead to improved financial efficiency at hospitals and a better quality of life for patients who can stay home in good, stable health instead of being rushed back to the hospital.
DarioHealth’s digital health diabetes management solution is designed to help hospital Certified Diabetes Educators (CDEs) and nurses support patients discharged from hospitals in managing their blood glucose levels. They immediately receive the information entered by the patient, including blood glucose measurement, so that they can provide relevant advice to the patient. Through the DarioEngage™ software, they can manage a population of patients and focus their attention on those needing the most support.
A scientific article5 titled, “Reducing Hospital Readmission: Current Strategies and Future Directions,” listed the components of ideal transition care from hospital to home that reduce readmission rates. These included: educating patients to promote self-management; enlisting the help of social and community supports; monitoring and managing symptoms after discharge, and outpatient follow-up.
The DarioHealth digital diabetes management system delivers on each of these components that reduce hospital readmissions, when the patient gives consent to share their data with the hospital and caregivers.
- Educating patients to promote self-management: Dario’s award winning next-generation Dario™ app integrates a comprehensive educational content library with a two-way-in app chat feature allowing direct communication in the context of the captured data.
- Enlisting the help of social and community supports: Users have the option of sharing their results with caregivers and family members through alerts, and through posting their results to social media, allowing friends and family to applaud their progress, thereby creating a positive feedback loop and community support.
- Monitoring and managing symptoms after discharge: Dario’s mobile phone integrated, pocket-size device yields highly accurate measurements in a few seconds. Blood glucose measurements are automatically recorded, providing an analysis of the user’s condition. The system allows simple logging of key diabetes metrics including carb counting, physical activity, and insulin intake. All of these metrics are available in real time for caregivers to access.
- Outpatient follow-up: The Dario system seamlessly integrates with its caregiver platform, DarioEngage™, used by nurses, CDEs and other healthcare professionals to track and follow up with their patients. Dario’s built-in emergency alerts use the GPS function of the phone to indicate the precise location of the patient.
Emergency room and hospital readmissions may end up costing hospitals thousands of dollars per patient. Avoiding these readmissions is a major goal of hospital systems in the U.S. and DarioEngage™ digital diabetes management platform may help hospitals reach this goal.
João Mendes-Roter is DarioHealth’s Vice President of Marketing. She is a marketing executive and online digital expert in growth marketing and direct response. Joao is pleased to apply her digital engagement expertise to improve the health and lives of people living with chronic disease. She has a proven track-record in increasing revenues and costumer experience, via better funnels, new products, effective online-offline marketing channels, and new business opportunities. Prior to joining DarioHealth, she held senior roles at 888 Holdings and gained valuable experience at RadView Software and Dun & Bradstreet.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company describes the benefits of its platform, describes potential cost savings, describes its potential user base, and describes potential future revenues, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
1, 2 Ostling S. “The relationship between diabetes mellitus and 30-day readmission rates”. 22 March 2017 in Clinical Diabetes and Endocrinology20173:3, https://doi.org/10.1186/s40842-016-0040-x
3,5 Kripalani S. “Reducing Hospital Readmission: Current Strategies and Future Directions”. Annu Rev Med. 2014; 65: 471–485. Published online 2013 Oct 21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104507/
4 Centers for Medicare & Medicaid Services. “Hospital Readmissions Reduction Program (HRRP)” https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html
6 DarioHealth “DarioHealth Presents New Data at American Diabetes Association’s 78th Scientific Sessions on June 25, 2018” June 25, 2018, http://mydario.investorroom.com/2018-06-25-DarioHealth-Presents-New-Data-at-American-Diabetes-Associations-78th-Scientific-Sessions-on-June-25-2018